Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Sensitive method for endotoxin determination in nanomedicinal product samples.

Giannakou C, Aimonen K, Bloois LV, Catalán J, Geertsma RE, Gremmer ER, de Jong WH, Keizers PH, Schwillens PL, Vandebriel RJ, Park MV.

Nanomedicine (Lond). 2019 May;14(10):1231-1246. doi: 10.2217/nnm-2018-0339.

PMID:
31124759
2.

Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink.

de Jong HJI, Cohen Tervaert JW, Lalmohamed A, de Vries F, Vandebriel RJ, van Loveren H, Klungel OH, van Staa TP.

PLoS One. 2018 Feb 23;13(2):e0193297. doi: 10.1371/journal.pone.0193297. eCollection 2018.

3.

The crystal structure of titanium dioxide nanoparticles influences immune activity in vitro and in vivo.

Vandebriel RJ, Vermeulen JP, van Engelen LB, de Jong B, Verhagen LM, de la Fonteyne-Blankestijn LJ, Hoonakker ME, de Jong WH.

Part Fibre Toxicol. 2018 Jan 30;15(1):9. doi: 10.1186/s12989-018-0245-5.

4.

A practical approach to assess inhalation toxicity of metal oxide nanoparticles in vitro.

Dankers ACA, Kuper CF, Boumeester AJ, Fabriek BO, Kooter IM, Gröllers-Mulderij M, Tromp P, Nelissen I, Zondervan-Van Den Beuken EK, Vandebriel RJ.

J Appl Toxicol. 2018 Feb;38(2):160-171. doi: 10.1002/jat.3518. Epub 2017 Sep 28.

PMID:
28960351
5.

Considerations for Safe Innovation: The Case of Graphene.

Park MVDZ, Bleeker EAJ, Brand W, Cassee FR, van Elk M, Gosens I, de Jong WH, Meesters JAJ, Peijnenburg WJGM, Quik JTK, Vandebriel RJ, Sips AJAM.

ACS Nano. 2017 Oct 24;11(10):9574-9593. doi: 10.1021/acsnano.7b04120. Epub 2017 Sep 26.

PMID:
28933820
6.

Nanomedicinal products: a survey on specific toxicity and side effects.

Brand W, Noorlander CW, Giannakou C, De Jong WH, Kooi MW, Park MV, Vandebriel RJ, Bosselaers IE, Scholl JH, Geertsma RE.

Int J Nanomedicine. 2017 Aug 22;12:6107-6129. doi: 10.2147/IJN.S139687. eCollection 2017.

7.

The effect of zirconium doping of cerium dioxide nanoparticles on pulmonary and cardiovascular toxicity and biodistribution in mice after inhalation.

Dekkers S, Miller MR, Schins RPF, Römer I, Russ M, Vandebriel RJ, Lynch I, Belinga-Desaunay MF, Valsami-Jones E, Connell SP, Smith IP, Duffin R, Boere JAF, Heusinkveld HJ, Albrecht C, de Jong WH, Cassee FR.

Nanotoxicology. 2017 Aug;11(6):794-808. doi: 10.1080/17435390.2017.1357214. Epub 2017 Aug 9.

PMID:
28741972
8.

Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study.

De Jong HJI, van Staa TP, Lalmohamed A, de Vries F, Vandebriel RJ, Van Loveren H, Klungel OH, Cohen Tervaert JW.

Ann Rheum Dis. 2017 Oct;76(10):1723-1730. doi: 10.1136/annrheumdis-2016-210936. Epub 2017 Jul 6.

PMID:
28684558
9.

Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop.

Bruysters MWP, Schiffelers MJ, Hoonakker M, Jungbaeck C, Ragan I, Rommel E, van der Stappen T, Viviani L, Hessel EV, Akkermans AM, Vandebriel RJ.

Biologicals. 2017 Jul;48:1-5. doi: 10.1016/j.biologicals.2017.06.006. Epub 2017 Jun 27.

PMID:
28666717
10.

Risk assessment of titanium dioxide nanoparticles via oral exposure, including toxicokinetic considerations.

Heringa MB, Geraets L, van Eijkeren JC, Vandebriel RJ, de Jong WH, Oomen AG.

Nanotoxicology. 2016 Dec;10(10):1515-1525. Epub 2016 Oct 11.

PMID:
27680428
11.

State of the art in non-animal approaches for skin sensitization testing: from individual test methods towards testing strategies.

Ezendam J, Braakhuis HM, Vandebriel RJ.

Arch Toxicol. 2016 Dec;90(12):2861-2883. Epub 2016 Sep 14. Review.

PMID:
27629427
12.

A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements.

Giannakou C, Park MV, de Jong WH, van Loveren H, Vandebriel RJ, Geertsma RE.

Int J Nanomedicine. 2016 Jun 22;11:2935-52. doi: 10.2147/IJN.S102385. eCollection 2016. Review.

13.

Towards a nanospecific approach for risk assessment.

Dekkers S, Oomen AG, Bleeker EA, Vandebriel RJ, Micheletti C, Cabellos J, Janer G, Fuentes N, Vázquez-Campos S, Borges T, Silva MJ, Prina-Mello A, Movia D, Nesslany F, Ribeiro AR, Leite PE, Groenewold M, Cassee FR, Sips AJ, Dijkzeul A, van Teunenbroek T, Wijnhoven SW.

Regul Toxicol Pharmacol. 2016 Oct;80:46-59. doi: 10.1016/j.yrtph.2016.05.037. Epub 2016 May 30. Review.

14.

Horizon scan of nanomedicinal products.

Noorlander CW, Kooi MW, Oomen AG, Park MV, Vandebriel RJ, Geertsma RE.

Nanomedicine (Lond). 2015 May;10(10):1599-608. doi: 10.2217/nnm.15.21. Epub 2015 Feb 19.

15.

In vitro innate immune cell based models to assess whole cell Bordetella pertussis vaccine quality: a proof of principle.

Hoonakker ME, Verhagen LM, Hendriksen CF, van Els CA, Vandebriel RJ, Sloots A, Han WG.

Biologicals. 2015 Mar;43(2):100-9. doi: 10.1016/j.biologicals.2014.12.002. Epub 2015 Jan 26.

PMID:
25633359
16.

Comparison of the molecular topologies of stress-activated transcription factors HSF1, AP-1, NRF2, and NF-κB in their induction kinetics of HMOX1.

Pronk TE, van der Veen JW, Vandebriel RJ, van Loveren H, de Vink EP, Pennings JL.

Biosystems. 2014 Oct;124:75-85. doi: 10.1016/j.biosystems.2014.09.005. Epub 2014 Sep 6.

PMID:
25199502
17.

Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats.

Vandebriel RJ, Tonk EC, de la Fonteyne-Blankestijn LJ, Gremmer ER, Verharen HW, van der Ven LT, van Loveren H, de Jong WH.

Part Fibre Toxicol. 2014 May 7;11:21. doi: 10.1186/1743-8977-11-21.

18.

Toward a mechanism-based in vitro safety test for pertussis toxin.

Vaessen SF, Bruysters MW, Vandebriel RJ, Verkoeijen S, Bos R, Krul CA, Akkermans AM.

Hum Vaccin Immunother. 2014;10(5):1391-5. doi: 10.4161/hv.28001. Epub 2014 Feb 19. Review.

19.

Sub-chronic toxicity study in rats orally exposed to nanostructured silica.

van der Zande M, Vandebriel RJ, Groot MJ, Kramer E, Herrera Rivera ZE, Rasmussen K, Ossenkoppele JS, Tromp P, Gremmer ER, Peters RJ, Hendriksen PJ, Marvin HJ, Hoogenboom RL, Peijnenburg AA, Bouwmeester H.

Part Fibre Toxicol. 2014 Feb 7;11:8. doi: 10.1186/1743-8977-11-8.

20.

Statin use and markers of immunity in the Doetinchem cohort study.

De Jong HJ, Damoiseaux JG, Vandebriel RJ, Souverein PC, Gremmer ER, Wolfs M, Klungel OH, Van Loveren H, Cohen Tervaert JW, Verschuren WM.

PLoS One. 2013 Oct 16;8(10):e77587. doi: 10.1371/journal.pone.0077587. eCollection 2013.

21.

Identification of biomarkers to detect residual pertussis toxin using microarray analysis of dendritic cells.

Vaessen SF, Verkoeijen S, Vandebriel RJ, Bruysters MW, Pennings JL, Bos R, Krul CA, Akkermans AM.

Vaccine. 2013 Oct 25;31(45):5223-31. doi: 10.1016/j.vaccine.2013.08.082. Epub 2013 Sep 18.

PMID:
24055089
22.

Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats.

De Jong WH, Van Der Ven LT, Sleijffers A, Park MV, Jansen EH, Van Loveren H, Vandebriel RJ.

Biomaterials. 2013 Nov;34(33):8333-43. doi: 10.1016/j.biomaterials.2013.06.048. Epub 2013 Jul 22.

23.

Response to 'Statins accelerate the onset of collagen type II-induced arthritis in mice'-authors' reply.

Vandebriel RJ, De Jong HJ, Gremmer ER, Klungel OH, Tervaert JW, Slob W, Van Der Laan JW, Van Loveren H.

Arthritis Res Ther. 2013 Mar 8;15(2):403. doi: 10.1186/ar4170. No abstract available.

24.

The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans.

Blaauboer BJ, Boekelheide K, Clewell HJ, Daneshian M, Dingemans MM, Goldberg AM, Heneweer M, Jaworska J, Kramer NI, Leist M, Seibert H, Testai E, Vandebriel RJ, Yager JD, Zurlo J.

ALTEX. 2012;29(4):411-25. doi: 10.14573/altex.2012.4.411.

PMID:
23138511
25.

Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure.

van der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z, Serrano-Rojero CS, Gremmer ER, Mast J, Peters RJ, Hollman PC, Hendriksen PJ, Marvin HJ, Peijnenburg AA, Bouwmeester H.

ACS Nano. 2012 Aug 28;6(8):7427-42. doi: 10.1021/nn302649p. Epub 2012 Aug 9.

PMID:
22857815
26.

Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach.

de Jong HJ, Saldi SR, Klungel OH, Vandebriel RJ, Souverein PC, Meyboom RH, Passier JL, van Loveren H, Cohen Tervaert JW.

PLoS One. 2012;7(7):e41289. doi: 10.1371/journal.pone.0041289. Epub 2012 Jul 23.

27.

Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users.

de Jong HJ, Vandebriel RJ, Saldi SR, van Dijk L, van Loveren H, Cohen Tervaert JW, Klungel OH.

Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):835-43. doi: 10.1002/pds.3291. Epub 2012 Jun 6.

PMID:
22674737
28.

Statins accelerate the onset of collagen type II-induced arthritis in mice.

Vandebriel RJ, De Jong HJ, Gremmer ER, Klungel OH, Tervaert JW, Slob W, Van Der Laan JW, Van Loveren H.

Arthritis Res Ther. 2012 Apr 26;14(2):R90. doi: 10.1186/ar3814.

29.

Strategies for the optimisation of in vivo experiments in accordance with the 3Rs philosophy.

Madden JC, Hewitt M, Przybylak K, Vandebriel RJ, Piersma AH, Cronin MT.

Regul Toxicol Pharmacol. 2012 Jun;63(1):140-54. doi: 10.1016/j.yrtph.2012.03.010. Epub 2012 Mar 21.

PMID:
22446816
30.

A review of mammalian toxicity of ZnO nanoparticles.

Vandebriel RJ, De Jong WH.

Nanotechnol Sci Appl. 2012 Aug 15;5:61-71. doi: 10.2147/NSA.S23932. Review.

31.

Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, Germany.

Peiser M, Tralau T, Heidler J, Api AM, Arts JH, Basketter DA, English J, Diepgen TL, Fuhlbrigge RC, Gaspari AA, Johansen JD, Karlberg AT, Kimber I, Lepoittevin JP, Liebsch M, Maibach HI, Martin SF, Merk HF, Platzek T, Rustemeyer T, Schnuch A, Vandebriel RJ, White IR, Luch A.

Cell Mol Life Sci. 2012 Mar;69(5):763-81. doi: 10.1007/s00018-011-0846-8. Epub 2011 Oct 14. Review.

32.

Use of statins is associated with an increased risk of rheumatoid arthritis.

de Jong HJ, Klungel OH, van Dijk L, Vandebriel RJ, Leufkens HG, van der Laan JW, Cohen Tervaert JW, van Loveren H.

Ann Rheum Dis. 2012 May;71(5):648-54. doi: 10.1136/ard.2011.155622. Epub 2011 Oct 6.

PMID:
21979000
33.

Association between statin use and lupus-like syndrome using spontaneous reports.

de Jong HJ, Tervaert JW, Saldi SR, Vandebriel RJ, Souverein PC, Meyboom RH, van Loveren H, Klungel OH.

Semin Arthritis Rheum. 2011 Dec;41(3):373-81. doi: 10.1016/j.semarthrit.2011.06.002. Epub 2011 Aug 24.

PMID:
21868063
34.

Response of MUTZ-3 dendritic cells to the different components of the Haemophilus influenzae type B conjugate vaccine: towards an in vitro assay for vaccine immunogenicity.

Hoefnagel MH, Vermeulen JP, Scheper RJ, Vandebriel RJ.

Vaccine. 2011 Jul 18;29(32):5114-21. doi: 10.1016/j.vaccine.2011.05.050. Epub 2011 May 30.

PMID:
21624423
35.

Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds.

Vandebriel RJ, Pennings JL, Baken KA, Pronk TE, Boorsma A, Gottschalk R, Van Loveren H.

Toxicol Sci. 2010 Sep;117(1):81-9. doi: 10.1093/toxsci/kfq182. Epub 2010 Jun 20.

PMID:
20566472
36.

Non-animal sensitization testing: state-of-the-art.

Vandebriel RJ, van Loveren H.

Crit Rev Toxicol. 2010 May;40(5):389-404. doi: 10.3109/10408440903524262. Review.

PMID:
20180632
37.

In vitro testing for direct immunotoxicity: state of the art.

Lankveld DP, Van Loveren H, Baken KA, Vandebriel RJ.

Methods Mol Biol. 2010;598:401-23. doi: 10.1007/978-1-60761-401-2_26.

PMID:
19967527
38.

The role of Toll-like receptor-4 in pertussis vaccine-induced immunity.

Banus S, Stenger RM, Gremmer ER, Dormans JA, Mooi FR, Kimman TG, Vandebriel RJ.

BMC Immunol. 2008 May 22;9:21. doi: 10.1186/1471-2172-9-21.

39.

Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses.

Geurtsen J, Fransen F, Vandebriel RJ, Gremmer ER, de la Fonteyne-Blankestijn LJ, Kuipers B, Tommassen J, van der Ley P.

Vaccine. 2008 Feb 13;26(7):899-906. doi: 10.1016/j.vaccine.2007.12.012. Epub 2007 Dec 31.

PMID:
18207288
40.

Comparative gene expression profiling in two congenic mouse strains following Bordetella pertussis infection.

Banus S, Vandebriel RJ, Pennings JL, Gremmer ER, Wester PW, van Kranen HJ, Breit TM, Demant P, Mooi FR, Hoebee B, Kimman TG.

BMC Microbiol. 2007 Oct 12;7:88.

41.

Genetic variation in the response to vaccination.

Kimman TG, Vandebriel RJ, Hoebee B.

Community Genet. 2007;10(4):201-17. Review.

PMID:
17895626
42.

Toll-like receptor 4 polymorphism associated with the response to whole-cell pertussis vaccination in children from the KOALA study.

Banus S, Bottema RW, Siezen CL, Vandebriel RJ, Reimerink J, Mommers M, Koppelman GH, Hoebee B, Thijs C, Postma DS, Kimman TG, Stelma FF.

Clin Vaccine Immunol. 2007 Oct;14(10):1377-80. Epub 2007 Aug 15.

43.

Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines.

Geurtsen J, Vandebriel RJ, Gremmer ER, Kuipers B, Tommassen J, van der Ley P.

Microbes Infect. 2007 Jul;9(9):1096-103. Epub 2007 May 17.

PMID:
17644385
44.

In vitro immunotoxicity of bis(tri-n-butyltin)oxide (TBTO) studied by toxicogenomics.

Baken KA, Arkusz J, Pennings JLA, Vandebriel RJ, van Loveren H.

Toxicology. 2007 Jul 31;237(1-3):35-48. doi: 10.1016/j.tox.2007.04.018. Epub 2007 May 5.

PMID:
17553608
45.

Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.

Geurtsen J, Banus HA, Gremmer ER, Ferguson H, de la Fonteyne-Blankestijn LJ, Vermeulen JP, Dormans JA, Tommassen J, van der Ley P, Mooi FR, Vandebriel RJ.

Clin Vaccine Immunol. 2007 Jul;14(7):821-9. Epub 2007 May 9.

46.

Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.

Vandebriel RJ, Gremmer ER, Vermeulen JP, Hellwig SM, Dormans JA, Roholl PJ, Mooi FR.

Vaccine. 2007 Mar 8;25(12):2346-60. Epub 2006 Dec 12.

PMID:
17224216
47.

Effects of a diphtheria-tetanus-acellular pertussis vaccine on immune responses in murine local lymph node and lung allergy models.

Vandebriel RJ, Gremmer ER, van Hartskamp M, Dormans JA, Mooi FR.

Clin Vaccine Immunol. 2007 Mar;14(3):211-9. Epub 2007 Jan 3.

48.

Toxicogenomics in the assessment of immunotoxicity.

Baken KA, Vandebriel RJ, Pennings JL, Kleinjans JC, van Loveren H.

Methods. 2007 Jan;41(1):132-41. Review.

PMID:
17161310
49.

Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology.

Banus HA, Vandebriel RJ, de Ruiter H, Dormans JA, Nagelkerke NJ, Mooi FR, Hoebee B, van Kranen HJ, Kimman TG.

Infect Immun. 2006 May;74(5):2596-605.

50.

In vitro assessment of sensitizing activity of low molecular weight compounds.

Vandebriel RJ, Van Och FM, van Loveren H.

Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):142-8. Review.

PMID:
16000204

Supplemental Content

Loading ...
Support Center